AIP
NBIX icon

Arrowpoint Investment Partners’s Neurocrine Biosciences NBIX Stock Holding History

Arrowpoint Investment Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.78M Sell
16,490
-5,066
-24% -$752K 0.61% 34
2026
Q1 		$2.84M Buy
21,556
+18,039
+513% +$2.39M 2.52% 8
2025
Q4 		$499K Buy
+3,517
New +$510K 0.07% 73

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowpoint Investment Partners's NBIX Position: Q2 2026 in Review

Arrowpoint Investment Partners reduced its Neurocrine Biosciences (NBIX) stake by 24% in Q2 2026, selling an estimated $752K and leaving 16,490 shares worth $2.78M. The position accounts for 0.61% of the portfolio, ranked #34.

Arrowpoint Investment Partners first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.84M in Q1 2026. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Arrowpoint Investment Partners held 16,490 shares of Neurocrine Biosciences worth $2.78M as of Q2 2026.
  • Arrowpoint Investment Partners sold 5,066 Neurocrine Biosciences shares in Q2 2026, an estimated $752K.
  • Neurocrine Biosciences made up 0.61% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #34 holding.
  • Arrowpoint Investment Partners first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Arrowpoint Investment Partners's Neurocrine Biosciences position peaked at $2.84M in Q1 2026.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.